Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients

2011542 citationsJournal Articlebronze Open Access

Authors

Samuel Z. Goldhaber · Harvard University

Alain Leizorovicz · Université Claude Bernard Lyon 1

Ajay K. Kakkar · University College London

Sylvia Haas · Technical University of Munich

Geno J. Merli · Jefferson University Hospitals

Robert M. Knabb · Bristol-Myers Squibb (United States)

Jeffrey I. Weitz

Abstract

In medically ill patients, an extended course of thromboprophylaxis with apixaban was not superior to a shorter course with enoxaparin. Apixaban was associated with significantly more major bleeding events than was enoxaparin. (Funded by Bristol-Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00457002.).

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Case Reports on Hematomas Atrial Fibrillation Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 365, Issue 23, pp. 2167-2177

DOI: 10.1056/nejmoa1110899

Field-Weighted Citation Impact: 45.86